Meeting
2021 ASCO Annual Meeting
Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).
Authors
Axel Bex
The Netherlands Cancer Institute, Amsterdam, Netherlands
Axel Bex , Yasmin Abu-Ghanem , Johannes V. Van Thienen , Niels Graafland , Brunolf Lagerveld , Patricia Zondervan , Harrie Beerlage , Jeroen van Moorselaar , Mark Kockx , Pieter-Jan Van Dam , Bernadett Szabados , Christian U. Blank , Thomas Powles , John B. A. G. Haanen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03341845
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4573)
DOI
10.1200/JCO.2021.39.15_suppl.4573
Abstract #
4573
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase 2, single-arm trial of neoadjuvant axitinb plus avelumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).
First Author: Axel Bex
Poster
2021 Genitourinary Cancers Symposium
A pilot study of preoperative nivolumab in high-risk nonmetastatic renal cell carcinoma.
First Author: Maria Isabel Carlo
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC).
First Author: Shun Zhang
Poster
2023 ASCO Genitourinary Cancers Symposium
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.
First Author: Nirmish Singla